A point-of-care device using single molecule array (simoa) to measure viral antigens in nasal swabs, saliva, and blood
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01EB033305
- Recipient
-
Quanterix Corporation UEI FMFEHF5ACEV2
- Awarding agency
-
National Institute of Biomedical Imaging and Bioenginering
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,941,087
Award facts
- Assistance listing
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- Completion date
- Place of performance
- Massachusetts, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of this project is to develop a simple-to-use, low-cost, and small instrument and associated consumable for point-of-care (POC) diagnoses based on the ultrasensitive detection of proteins. The proposed system will combine detection of proteins using the single molecule array (simoa; quanterix corporation) technology and assay processing using digital microfluidics (DMF) to enable POC immunoassays with the sensitivity and specificity of nucleic acid amplification tests without the need for nucleic acid purification or amplification, and with the simplicity, sample type flexibility, and diagnostic performance to deliver central lab diagnostic quality in POC settings. The proposed system would be composed of a sample- to-answer, random access, benchtop instrument utilizing a universal consumable design accepting a broad range of minimally processed samples relevant to POC diagnosis of disease, including swab, saliva, and blood (including fingerstick) samples. We will first apply this technology to the diagnosis of covid-19 and influenza, optimizing existing assays for sars-COV-2 n-protein and developing new multiplexed assays for influenza a and b antigens, along with simple sample preparation methods, for testing of nasal/nasopharyngeal (NP) swab (sars-COV-2/influenza) and saliva/blood (sars-COV-2 only) samples. This project-a collaboration between quanterix (DR. Duffy, CO-PI), boston children's hospital (DR. Pollock, CO-PI), and university of toronto (DR. Wheeler, CO-investigator)-has four specific aims to achieve these goals. First, we will develop the key technologies to enable the POC system, namely: a low-cost simoa imager with a small form factor; single molecule labels that do not require sealing in microwell arrays; and, the DMF building blocks for assay processing, resulting in an integrated simoa-DMF device. Second, we will design, develop, and test simoa POC instruments and consumables, first in prototype and then for test validation. Third, we will optimize/develop and validate analytically simoa assays (including sample preparation options) for sars- COV-2 (nasal swab, saliva, blood) and multiplex influenza a/b (NP swab) antigens, and test them on the prototype simoa POC system. Finally, we will clinically validate the POC antigen tests against gold-standard molecular tests for all sample types using discarded/banked clinical samples, and evaluate performance of the POC system in POC settings using contrived clinical samples. User feedback will inform development throughout the proposal. The long-term objective of this research is to develop a broadly enabling technology that would allow the diagnosis of diseases using ultrasensitive protein detection at the POC in a small, low-cost benchtop system. This type of capability is available for molecular testing but not for protein detection, and would combine high sensitivity with low cost and an alternative supply chain to support diagnosis of infectious diseases in diverse clinical settings. This system would be a critical new diagnostic tool ready both for routine POC diagnosis of infectious diseases and to benefit the world in the event of the next pandemic.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$174,384 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,705,157 | |
| Amendment | $1,705,157 | |
| Original award | $1,705,157 |
Quick answers
Who received award U01EB033305?
U01EB033305 was awarded to Quanterix Corporation by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 22, 2022.
How much is award U01EB033305 worth?
$4,941,087 has been obligated on U01EB033305.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award